Pan Cancer T secures €4.25 Million in Seed Extension Round to advance next-generation T cell therapies
Summary
This round includes a new investor InnovationQuarter and continued support from existing investors: Van Herk Ventures, Thuja Capital, Swanbridge Capital and Erasmus MC O&O Holdings, bringing Pan Cancer Ts total funding to approximately 11 million. As a result, Investment Manager of InnovationQuarter Nina Satih will take a Supervisory Board observer role.The Seed Extension Round will allow Pan Cancer T to complete preclinical studies for its lead TCR-T cell product, PCT1:CO-STIM, and progress CMC activities, thereby creating value and derisking the project. Moreover, it incorporates a proprietary TME solution, which provides co-stimulation to T cells, even in the hostile TME, resulting in significantly improved response duration in preclinical models.About Pan Cancer TPan Cancer T was founded in late 2020 as a spin-off from Erasmus MC (Rotterdam, the Netherlands) to advance next generation TCR T cell therapies for hard-to-treat solid tumors. With a combination of funding, extensive knowledge across multiple sectors, a very broad network and great involvement, we create strong, innovative ecosystems. With four funds, we invest in and support innovative, fast-growing local enterprises, as well as assist foreign companies in establishing themselves in this region.